Mentara Bio
Mentara Bio is a pioneering biopharmaceutical company dedicated to developing innovative therapies for neurological disorders, including epilepsy, Parkinson's disease, and multiple sclerosis. They utilize cutting-edge brain science, advanced technologies, and precision medicine approaches to create targeted treatments that aim to restore neural function and improve patients' quality of life. Their research focuses on neurotransmitter modulation, neuroinflammation, and neurogenesis, with a strong emphasis on safety, efficacy, and addressing unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Mentara Bio
Products
Lead glutamate-modulating clinical candidate for epilepsy
A small-molecule glutamate pathway modulator intended to stabilize neuronal firing and reduce seizure frequency by modulating glutamatergic signaling.
Noncompetitive NMDA antagonist candidate for Parkinson's disease
A noncompetitive, low-trapping NMDA receptor antagonist in clinical development to reduce motor symptoms and improve quality of life in Parkinson’s disease.
Clinical-stage candidate for Tourette syndrome and other CNS indications
A development-stage candidate listed for Tourette syndrome and other central nervous system (CNS) indications as part of the product pipeline.
Lead glutamate-modulating clinical candidate for epilepsy
A small-molecule glutamate pathway modulator intended to stabilize neuronal firing and reduce seizure frequency by modulating glutamatergic signaling.
Noncompetitive NMDA antagonist candidate for Parkinson's disease
A noncompetitive, low-trapping NMDA receptor antagonist in clinical development to reduce motor symptoms and improve quality of life in Parkinson’s disease.
Clinical-stage candidate for Tourette syndrome and other CNS indications
A development-stage candidate listed for Tourette syndrome and other central nervous system (CNS) indications as part of the product pipeline.
Services
Collaborative development agreements and licensing/partnership opportunities with academic groups and external inventors to advance neurological therapeutics.
Internal conduct and operational management of clinical studies for neurological indications, including site coordination and participant evaluation.
Collaborative development agreements and licensing/partnership opportunities with academic groups and external inventors to advance neurological therapeutics.
Internal conduct and operational management of clinical studies for neurological indications, including site coordination and participant evaluation.
Expertise Areas
- Clinical trial management (Phase 1–2)
- Drug discovery for neurological disorders (glutamate-targeted small molecules)
- Precision medicine and biomarker development
- CMC and formulation development for oral therapeutics
Key Technologies
- Noncompetitive NMDA receptor antagonism (low-trapping)
- Glutamate pathway modulation
- Biomarker-driven patient stratification
- Imaging-based phenotyping
News & Updates
Mentara Bio announced plans to commence a Phase 2 clinical trial of MN-302 for epilepsy.
Mentara Bio successfully closed a $4.1 million Series A financing round to support IND-enabling studies for MN-045.
Mentara Bio announced its official launch with a focus on developing treatments for epilepsy and related disorders, including MN-045.
Mentara Bio announced plans to commence a Phase 2 clinical trial of MN-302 for epilepsy.
Mentara Bio successfully closed a $4.1 million Series A financing round to support IND-enabling studies for MN-045.
Mentara Bio announced its official launch with a focus on developing treatments for epilepsy and related disorders, including MN-045.